---
title: "Top 10 HK Stock Gainers (11.14)"
description: "REFIRE(02570) rose 40.56%, with a trading turnover 830.0 Million HKD, and a year-to-date fell 9.5%. VIGONVITA-B(02630) rose 23.89%, with a trading turnover 38.6 Million HKD, and a year-to-date rose 10"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/266061224.md"
published_at: "2025-11-16T08:30:51.000Z"
---

# Top 10 HK Stock Gainers (11.14)

> REFIRE(02570) rose 40.56%, with a trading turnover 830.0 Million HKD, and a year-to-date fell 9.5%. VIGONVITA-B(02630) rose 23.89%, with a trading turnover 38.6 Million HKD, and a year-to-date rose 104.4%. ASCLETIS-B(01672) rose 15.46%, with a trading turnover 248.8 Million HKD, and a year-to-date rose 356.5%.

Hang Seng Index has fell 1.85%, with a year-to-date rose 32.5%; Hang Seng TECH Index has fell 2.82%, with a year-to-date rose 30.1%.

REFIRE(02570) rose 40.56%, with a trading turnover 830.0 Million HKD, and a year-to-date fell 9.5%.

VIGONVITA-B(02630) rose 23.89%, with a trading turnover 38.6 Million HKD, and a year-to-date rose 104.4%.

ASCLETIS-B(01672) rose 15.46%, with a trading turnover 248.8 Million HKD, and a year-to-date rose 356.5%.

### Related Stocks

- [02570.HK - REFIRE](https://longbridge.com/en/quote/02570.HK.md)
- [02630.HK - VIGONVITA-B](https://longbridge.com/en/quote/02630.HK.md)
- [01672.HK - ASCLETIS-B](https://longbridge.com/en/quote/01672.HK.md)
- [02039.HK - CIMC](https://longbridge.com/en/quote/02039.HK.md)
- [02105.HK - LAEKNA-B](https://longbridge.com/en/quote/02105.HK.md)
- [02565.HK - PEGBIO CO-B](https://longbridge.com/en/quote/02565.HK.md)
- [01983.HK - LUZHOU BANK](https://longbridge.com/en/quote/01983.HK.md)
- [02616.HK - CSTONE PHARMA-B](https://longbridge.com/en/quote/02616.HK.md)
- [02225.HK - JINHAI MED TECH](https://longbridge.com/en/quote/02225.HK.md)
- [09900.HK - ZCLOUD TECH CON](https://longbridge.com/en/quote/09900.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CStone secures FDA clearance to begin CS2009 Phase II trial | CStone Pharmaceuticals has received FDA clearance for its IND application, allowing the initiation of a Phase II trial f | [Link](https://longbridge.com/en/news/276114397.md) |
| Ascletis Pharma Raises HK$844 Million in Private Share Placement | Ascletis Pharma Inc. has successfully raised HK$844 million through a private placement of 69,256,000 new shares at HK$1 | [Link](https://longbridge.com/en/news/275434090.md) |
| Ascletis Pharma Boosts Share Buyback Plan to HK$500 Million | Ascletis Pharma Boosts Share Buyback Plan to HK$500 Million | [Link](https://longbridge.com/en/news/269948463.md) |
| Ascletis Pharma kündigt Privatplatzierung neuer Aktien an | Ascletis Pharma Inc. has announced a private placement of new shares under a general mandate. The shares will be offered | [Link](https://longbridge.com/en/news/274571020.md) |
| Shanghai Refire Group Announces Private Placement of New H Shares | Shanghai Refire Group Ltd. has announced a private placement of new H shares under a general mandate. The shares will no | [Link](https://longbridge.com/en/news/272909421.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.